The recognition that atherosclerosis is a complex chronic inflammatory disorder mediated
through both adaptive and innate immunity has led to the hypothesis that anticytokine …

Plasma levels of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP)
predict vascular risk with an effect estimate as large as that of total or high-density …

As biologic, epidemiologic, and clinical trial data have demonstrated, inflammation is a key
driver of atherosclerosis. Circulating biomarkers of inflammation, including high-sensitivity C …

Atherosclerotic cardiovascular disease is a leading cause of death and morbidity globally.
Over the past several years, arterial inflammation has been implicated in the …

Inflammation contributes to all phases of the atherothrombotic process, patients with
elevated inflammatory biomarkers such as high-sensitivity C-reactive protein (hsCRP) have …

The role of inflammation in atherosclerosis has been recognized several decades ago and
existing treatments provide benefits in part through non-specific anti-inflammatory actions …

Chronic subclinical inflammation is a key process in the pathogenesis of atherosclerotic
cardiovascular disease (ASCVD). Along with lipids, inflammation is essential for the initiation …

Atherothrombosis is no longer considered solely a disorder of lipoprotein accumulation in
the arterial wall. Rather, the initiation and progression of atherosclerotic lesions is currently …

Aims Targeting vascular inflammation represents a novel therapeutic approach to reduce
complications of atherosclerosis. Neutralizing the pro-inflammatory cytokine interleukin-1β …

Despite major advances in prevention and treatment, cardiac and cerebral atherothrombotic
complications still account for substantial morbidity and mortality worldwide. In this context …